IRCT2015112925284N1CompletedPhase 2
Effectiveness of simvastatin on improvement of multiple sclerosis (MS).
Vice Chancellor for Research, Arak University of Medical Sciences0 sites60 target enrollmentStarted: TBDLast updated:
Conditions
Trial Snapshot
- Phase
- Phase 2
- Status
- Completed
- Sponsor
- Enrollment
- 60
Study Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Interventional
Eligibility Criteria
- Ages
- 18 years to 60 years (—)
- Sex
- All
Inclusion Criteria
- •Relapsing-remitting MS patients; at least 1 relapse in the previous 12 months; more than three lesions on spinal or brain magnetic resonance imaging or both; baseline expanded disability status scale (EDSS) from 0 to 3.5; aged 18–60 years.
- •Exclusion criteria: clinical CIS syndrome, progressive MS, MS patients with acute clinical relapses occurring during the study, drug abuse, renal failure, pregnancy, hepatitis diseases.
Exclusion Criteria
- Not provided
Investigators
Similar Trials
Recruiting
Phase 2
Effect of simvastatin in treatment of pachyonychia congenitaIRCT20160320027109N3Shahid Beheshti University of Medical Sciences20
Completed
Not Applicable
Comparing the bone regeneration capacity along with different clinical criteria of xenograft and simvastatiCTRI/2022/10/046426Punjab Government Dental College and Hospital Amritsar22
Recruiting
Phase 2
Protective effect of simvastatin on inflammatory factorIRCT20200421047152N3Iran University of Medical Sciences84
Recruiting
Not Applicable
Effect of Simvastatin in Treatment of Uterine LeiomyomaIRCT20080831001141N34Royan Institute60
Completed
Phase 3
The effect of oral simvastatin on the outcome of patients with severe traumatic brain injurySevere traumatic brain injury.IRCT20180802040668N1Sari University of Medical Sciences98